Hemos has joined Chongqing’s biomanufacturing pilot platform, accelerating the industrialization of Recombinant Keratin across the board.

Biomanufacturing is a national…   The new growth pole prioritized for development during the 15th Five-Year Plan has been designated by the Fourth Plenary Session of the 20th CPC Central Committee as a key strategic area, alongside quantum technology and brain–machine interfaces. Chongqing Municipality has incorporated it into its “6+3” high-growth future industries framework and the “33618” modern manufacturing cluster system, making every effort to build a biopharmaceutical industry cluster with an output value exceeding 100 billion yuan.

The Chongqing Biomanufacturing Industry Pilot-Scale Platform has a total investment of RMB 625 million. Addressing the industry’s core pain points—“easy at the smallscale, difficult at the pilot scale, unstable scaleup, and sluggish technology transfer”—it has established a… R&D—Pilot Production—Maturation—Mass Production “A professional support system with end-to-end closed-loop capabilities:”

This platform fills the gap in specialized biomanufacturing pilot‑scale infrastructure in Southwest China, fundamentally addressing the bottleneck that has long hindered the translation of laboratory‑level research into industrial-scale production.

Hemos Biosciencetech, driven by synthetic biology as its core technology, focuses on the research, development, and industrialization of Recombinant Keratin. Its core products have already been commercialized in fields such as hair care, skincare, and oral care.

By establishing a presence on the national-level pilot‑scale testing platform, the company will gain triple momentum in scaling up and commercializing its core technologies:

The platform’s technological validation and resource coordination will strongly facilitate the green manufacturing and large-scale application of Recombinant Keratin. 
 

With innovative companies such as Hemos successively setting up operations, Chongqing’s biomanufacturing pilot‑scale platform is accelerating the development of a diversified industrial ecosystem centered on biopharmaceuticals, greater health, and green agriculture, striving to establish a new biomanufacturing hub that leads the Southwest and enjoys national renown, thereby jointly driving the high‑end, intelligent, and green transformation of Chongqing’s biomanufacturing industry.

Starting from fundamental research conducted in Chongqing University’s laboratories, Hemos Bioscience is forging a complete innovation pathway from “laboratory to production line.” This move to establish a pilot-scale platform represents both the most critical link in that pathway and a milestone marking the company’s true entry onto the fast track of industrialization. 
 

In the future, Hemos Bioscience will continue to deepen its expertise in the field of Recombinant Keratin, solidifying its development foundation through biotechnology and expanding industry boundaries with intelligent manufacturing. It will further strengthen its industrial presence in the Southwest region, contributing to the high-quality development of China’s bio-manufacturing sector and jointly creating a bright future in the life and health field.